Company news
Can-Fite BioPharma Ltd. news in 2026
Can-Fite BioPharma Ltd.'s news releases, calls and decks from 2026, newest first.
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
September 8, 2026
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
May 18, 2026
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
May 13, 2026
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
April 30, 2026
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
March 30, 2026
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
March 26, 2026
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
March 17, 2026
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
March 4, 2026
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
February 17, 2026
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
February 9, 2026
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
February 5, 2026
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
January 20, 2026